How common is NAION with semaglutide?

A European review estimated up to 1 in 10,000 people taking it — the very rare category. The MHRA describes it as a likely association.

What should someone do if they have symptoms?

The MHRA guidance is urgent referral for specialist ophthalmological examination. This is a clinical matter for a prescriber, not something to self-assess.

Why does the MHRA mention private prescriptions?

Because privately prescribed semaglutide may not appear on a patient's medical record, so a clinician may not know it is being taken unless they ask.

Research & Regulatory News

MHRA Drug Safety Update: Semaglutide and NAION

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

The MHRA issued a Drug Safety Update on 5 February 2026 warning of a likely association between semaglutide — Wegovy, Ozempic and Rybelsus — and non-arteritic anterior ischaemic optic neuropathy. A European review estimated the frequency at up to 1 in 10,000 people taking it.

Key facts

Issued: 5 February 2026
Regulator: MHRA (United Kingdom)
Products: Wegovy, Ozempic, Rybelsus
Condition: Non-arteritic anterior ischaemic optic neuropathy
Estimated frequency: Up to 1 in 10,000
Presentation: Sudden painless vision loss in one eye
Action if confirmed: Discontinue semaglutide

What NAION is

Non-arteritic anterior ischaemic optic neuropathy is damage to the optic nerve head caused by reduced blood supply, not by inflammation of the arteries — which is what the non-arteritic distinction means. It typically presents as sudden, painless loss or blurring of vision in one eye. It is uncommon in the general population and the visual loss is frequently permanent.

What the MHRA said

The Drug Safety Update of 5 February 2026 describes a likely association between semaglutide and NAION across all three UK products — Wegovy, Ozempic and Rybelsus. A European review estimated the frequency at up to 1 in 10,000 people taking semaglutide, which places it in the very rare category. The guidance is that patients presenting with these symptoms should be urgently referred for specialist ophthalmological examination, and that semaglutide should be discontinued if NAION is confirmed.

The detail specific to the UK market

The update makes a point that says a great deal about how these medicines are actually obtained here: semaglutide may not appear on a patient's medical record when it has been privately prescribed, so anyone presenting with these symptoms should be asked directly about semaglutide use. A large private prescription market means the drug history in front of a clinician may be incomplete, and the guidance is written around that reality rather than around an idealised record.

Where the signal came from

The published work behind it includes a 2024 study in JAMA Ophthalmology by Hathaway and colleagues examining NAION risk in patients prescribed semaglutide, followed by further analysis by Cai and colleagues in the same journal in 2025. A regulator issuing a safety update on that basis is the pharmacovigilance system working as designed — a signal detected, investigated, and communicated with a frequency estimate attached.

How to read a 1-in-10,000 estimate

Very rare, and worth stating carefully in both directions. It does not mean the association is unimportant — permanent vision loss is a serious outcome and the population taking semaglutide is very large, so a rare event across millions of users is not a small number of people. It also does not mean the risk is established as causal; regulators use language such as likely association precisely because the evidence supports action without establishing mechanism.

What this has to do with research material

Nothing directly, and the distinction is worth making. This is a safety communication about licensed medicines prescribed to patients and monitored through a pharmacovigilance system. Material supplied for laboratory research sits outside that system entirely — which is a limitation of research material rather than a reassurance about it. There is no equivalent monitoring, no Yellow Card signal detection, and no regulator issuing updates.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

How common is NAION with semaglutide?: A European review estimated up to 1 in 10,000 people taking it — the very rare category. The MHRA describes it as a likely association.
What should someone do if they have symptoms?: The MHRA guidance is urgent referral for specialist ophthalmological examination. This is a clinical matter for a prescriber, not something to self-assess.
Why does the MHRA mention private prescriptions?: Because privately prescribed semaglutide may not appear on a patient's medical record, so a clinician may not know it is being taken unless they ask.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum